Methods and compositions are provided for the identification of a molecular diagnostic test for lung cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether ...
Graphical Summary: Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer Read Moreabout Graphical Summary: Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung ca...
Search Test Menu Behind every biomarker is an opportunity to provide precise answers. Featured tests Behind every cancer diagnosis is someone waiting for options. Behind every biopsy is someone waiting for answers. Liquid biopsy Behind every biomarker is an opportunity to provide precise answers. ...
the GeneStrat NGS® genomic test and the VeriStrat® proteomic test for a broader view of each patient's disease state, with results in 3 business days.* IQLung testing empowers care teams with a testing strategy for any stage of non-small cell lung cancer (NSCLC) and delivers timely ...
the GeneStrat NGS® genomic test and the VeriStrat® proteomic test for a broader view of each patient's disease state, with results in 3 business days.* IQLung testing empowers care teams with a testing strategy for any stage of non-small cell lung cancer (NSCLC) and delivers timely ...
I: Initial clinical evaluation as a marker for colorectal cancer Since the CSAp test was less frequently elevated (0鈥 7%) in patients with breast, ovarian, lung, or cervical cancer than was found for CEA (39鈥 ... KD Pant,S Dan,MONO Medicine,... - 《Cancer》 被引量: 37发表: 1982...
The present disclosure provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer, such as lung cancer, pancreatic cancer and skin cancer, for monitoring the effectiveness of cancer, such as lung cancer... Lindsey Jane HUDSON 被引量: 3发表: 2014年 Diagnostic Yiel...
Lung cancer remains the leading cause of cancer deaths worldwide. Although low-dose spiral computed tomography (LDCT) screening is used for the detection of lung cancer in a high-risk population, false-positive results of LDCT remain a clinical problem. Here, we developed a blood test of a ...
Development of a PD- L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (pembro; MK-3475) in non-small cell lung cancer (NSCLC). Proceedings: ASCO Annual Meeting; May 29-June 2, 2015; Chicago ... Marisa Dolled-Filhart,Marisa Dolled-Filhart,Charlotte M...
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer The First US FDA Approved Non-invasive (BLOOD) EGFR Mutation Test for Lung Cancer Targeted Therapy Using Liquid Biopsy ...